2 Biotech Growth Stocks I'd Buy Right Now
Since the beginning of 2023, equity markets have been experiencing what could be the start of a bull run. Buying shares of growth stocks is an excellent move for investors looking to ride this wave. And while there are plenty of options on the market, looking at the healthcare industry -- where many businesses remain somewhat stable regardless of economic conditions -- could be just what the doctor ordered, considering we are still facing some economic issues.
In that spirit, let's examine two growth stocks in the biotech industry worth investing in today: Sarepta Therapeutics (NASDAQ: SRPT) and Exelixis (NASDAQ: EXEL).
Sarepta Therapeutics is a biotech company that develops therapies for rare illnesses, especially Duchenne muscular dystrophy (DMD). This progressive genetic disease is accompanied by several symptoms, most notably muscular weakness. Sarepta Therapeutics has developed four treatments for DMD already, but the latest looks the most promising.
Source Fool.com
Sarepta Therapeutics Stock
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
With a target price of 130 € there is a slightly positive potential of 15.56% for Sarepta Therapeutics compared to the current price of 112.5 €.
